Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma.

Autor Seto, M, Jaeger, U, Hockett, R D, Graninger, W, Bennett, S, Goldman, P, Korsmeyer, S J
Vydáno 1988

BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils

Autor Smiljkovic, D., Blatt, K., Stefanzl, G., Dorofeeva, Y., Skrabs, C., Focke‐Tejkl, M., Sperr, W. R., Jaeger, U., Valenta, R., Valent, P.
Vydáno v Allergy (2017)

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

Autor Smolen, J S, Keystone, E C, Emery, P, Breedveld, F C, Betteridge, N, Burmester, G R, Dougados, M, Ferraccioli, G, Jaeger, U, Klareskog, L, Kvien, T K, Martin‐Mola, E, Pavelka, K
Vydáno 2007

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

Autor Maurer, M J, Habermann, T M, Shi, Q, Schmitz, N, Cunningham, D, Pfreundschuh, M, Seymour, J F, Jaeger, U, Haioun, C, Tilly, H, Ghesquieres, H, Merli, F, Ziepert, M, Herbrecht, R, Flament, J, Fu, T, Flowers, C R, Coiffier, B
Vydáno v Ann Oncol (2018)

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib

Autor Kazianka, L, Drucker, C, Skrabs, C, Thomas, W, Melchardt, T, Struve, S, Bergmann, M, Staber, P B, Porpaczy, E, Einberger, C, Heinz, M, Hauswirth, A, Raderer, M, Pabinger, I, Thalhammer, R, Egle, A, Wendtner, C-M, Follows, G, Hoermann, G, Quehenberger, P, Jilma, B, Jaeger, U
Vydáno v Leukemia (2017)

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

Autor Brown, J R, Hillmen, P, O’Brien, S, Barrientos, J C, Reddy, N M, Coutre, S E, Tam, C S, Mulligan, S P, Jaeger, U, Barr, P M, Furman, R R, Kipps, T J, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, J M, Munir, T, Burger, J A, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, D F, Byrd, J C
Vydáno v Leukemia (2018)

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

Autor Byrd, J.C., Brown, J.R., O’Brien, S., Barrientos, J.C., Kay, N.E., Reddy, N.M., Coutre, S., Tam, C.S., Mulligan, S.P., Jaeger, U., Devereux, S., Barr, P.M., Furman, R.R., Kipps, T.J., Cymbalista, F., Pocock, C., Thornton, P., Caligaris-Cappio, F., Robak, T., Delgado, J., Schuster, S.J., Montillo, M., Schuh, A., de Vos, S., Gill, D., Bloor, A., Dearden, C., Moreno, C., Jones, J.J., Chu, A.D., Fardis, M., McGreivy, J., Clow, F., James, D.F., Hillmen, P.
Vydáno 2014